Your browser doesn't support javascript.
loading
Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates.
Santos, Joana M O; Costa, Alexandra C; Dias, Tânia R; Satari, Setareh; Costa E Silva, Maria Paula; da Costa, Rui M Gil; Medeiros, Rui.
Afiliação
  • Santos JMO; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal.
  • Costa AC; Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal.
  • Dias TR; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal.
  • Satari S; Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal.
  • Costa E Silva MP; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal.
  • da Costa RMG; Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal.
  • Medeiros R; Research Department of the Portuguese League against Cancer-Regional Nucleus of the North (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), 4200-177 Porto, Portugal.
Pharmaceuticals (Basel) ; 14(11)2021 Oct 26.
Article em En | MEDLINE | ID: mdl-34832866
ABSTRACT
As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or repositioning consists of the investigation of pharmacological components that are already available or in clinical trials for certain diseases and explores if they can be used for new indications. Its advantages comparing to de novo drugs development are the reduced amount of time spent and costs. In this paper, we selected drugs already available or in clinical trials for non-cachexia indications and that are related to the pathways and molecular components involved in the different phenotypes of cancer cachexia syndrome. Thus, we introduce known drugs as possible candidates for drug repurposing in the treatment of cancer-induced cachexia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2021 Tipo de documento: Article